ALZHEIMER'S DISEASE DIAGNOSIS AND TREATMENTS -- ALZHEIMER'S DISEASE DIAGNOSIS AND TREATMENTS -- CONTENTS -- PREFACE -- Chapter 1 ALZHEIMER'S DISEASE - 100 YEARS OF RESEARCH A HISTORICAL PERSPECTIVE AND COMMENTARY -- REFERENCES -- Chapter 2 CONTROLLED AND AUTOMATIC MEMORY PROCESSING IN ALZHEIMER'S DISEASE -- ABSTRACT -- INTRODUCTION -- TASK DISSOCIATION APPOACHES -- Processing Theories -- System Theories -- PROCESS DISSOCIATION APPROACHES -- Process-Dissociation Procedure -- Processing Dissociations in Alzheimer's Disease -- Processing Dissociations in Normal Ageing and Alzheimer's Disease -- Evidence from Brain Imaging Studies -- FUTURE DIRECTIONS -- CONCLUSION -- REFERENCES -- Chapter 3 AGE OF ONSET RELATED DIFFERENCES IN CLINICAL AND NEUROPSYCHOLOGICAL FEATURES OF ALZHEIMER'S DISEASE -- ABSTRACT -- INTRODUCTION -- RELATIONSHIP BETWEEN AGE OF ONSET AND CLINICAL AND NEUROPSYCHOLOGICAL FEATURES OF ALZHEIMER'S DISEASE -- Typical Clinical and Neuropsychological Features of Alzheimer's Disease -- Age of Onset Related Differences in Clinical and Neuropsychological Features of Alzheimer's Disease -- NEUROIMAGING AND AGE OF ONSET RELATED DIFFERENCES IN CLINICAL FEATURES OF ALZHEIMER'S DISEASE -- Structural Neuroimaging Findings -- Functional Neuroimaging Findings -- CONCLUSION -- ACKNOWLEDGMENT -- REFERENCES -- Chapter 4 EARLY ONSET DEMENTIA WITH ABUNDANT NON-NEURITIC A PLAQUES AND WITHOUT SIGNIFICANT NEURONAL LOSS: REPORT OF TWO JAPANESE AUTOPSY CASES -- ABSTRACT -- INTRODUCTION -- MATERIALS AND METHODS -- CASE REPORTS -- Case 1 -- Clinical Course -- Pathological Findings -- Case 2 -- Clinical Course -- Pathological Findings -- DISCUSSION -- ACKNOWLEDGMENT -- REFERENCES -- Chapter 5 HOW AND WHERE DOES Aβ EXERT ITS TOXIC EFFECTS IN ALZHEIMER'S DISEASE? -- INTRODUCTION -- INTRANEURONAL Aβ1-42 ACCUMULATION AND AGGREGATION.

WHAT IS THE ROLE OF EXTRACELLULAR Aβ? -- THE INTERACTION OF EXTRACELLULAR Aβ WITH THE CLEARANCE PATHWAYS -- Aβ AND LONG TERM POTENTIATION -- Aβ AND NICOTINIC NEUROTRANSMISSION -- Aβ AND ELECTRICAL PROPERTIES OF MEMBRANES -- THE ROLE OF OXIDATIVE STRESS -- CONCLUSION -- REFERENCES -- Chapter 6 THE SPATIAL PATTERNS OF -AMYLOID (A) DEPOSITS AND NEUROFIBRILLARY TANGLES (NFT) IN LATE-ONSET SPORADIC ALZHEIMER'S DISEASE -- ABSTRACT -- INTRODUCTION -- MATERIALS AND METHODS -- Cases -- Tissue Preparation -- Morphometric Methods -- Data Analysis -- RESULTS -- DISCUSSION -- CONCLUSION -- ACKNOWLEDGMENTS -- REFERENCES -- Chapter 7 BRAIN FUNCTION IN ALTERED STATES OF CONSCIOUSNESS: COMPARISON BETWEEN ALZHEIMER DEMENTIA AND VEGETATIVE STATE -- ABSTRACT -- INTRODUCTION -- "CONSCIOUSNESS" IN AD -- Vegetative State -- GLOBAL CEREBRAL METABOLISM IN VS AND IN AD -- Regional Metabolic Distribution -- FUNCTIONAL CONNECTIVITY -- CONCLUSIONS -- ACKNOWLEDGMENTS -- REFERENCES -- Chapter 8 COGNITIVE DEFICITS IN MILD COGNITIVE IMPAIRMENT -- ABSTRACT -- DEFINITION OF MCI -- PREVALENCE OF MCI -- PROGNOSIS OF MCI -- MEMORY DISTURBANCES IN MCI -- IMPLICATIONS FOR COGNITIVE REHABILITATION -- REFERENCES -- Chapter 9 MITOCHONDRIAL PATHOLOGY AND ALZHEIMER'S DISEASE -- ABSTRACT -- INTRODUCTION -- MITOCHONDRIA COMPARTMENT -- MITOCHONDRIA ARE MORPHOLOGICALLY ABNORMAL IN AD -- MITOCHONDRIAL DYSFUNCTION IN AD -- MITOCHONDRIAL RESPIRATORY CHAIN ENZYMES IN AD PATIENTS -- OXIDATIVE STRESS RELATED TO MITOCHONDRIAL DYSFUNCTION IN AD -- THE "CYBRID MODEL" OF AD -- MITOCHONDRIAL GENETICS AND AD -- CONCLUSION -- REFERENCES -- Chapter 10 CALMODULIN BINDS TO AND REGULATES THE ACTIVITY OF BETA-SECRETASE (BACE1) -- ABSTRACT -- INTRODUCTION -- MATERIAL AND METHODS -- BACE1 Enzyme Analysis -- CaM-Agarose Binding Assay -- RESULTS AND DISCUSSION -- CONCLUSION -- ACKNOWLEDGMENTS.

REFERENCES -- Chapter 11 TRANSGENIC MODELS OF ALZHEIMER'S PATHOLOGY: SUCCESS AND CAVEATS -- ABSTRACT -- INTRODUCTION -- NEUROPATHOLOGY -- At the Macroscopical Level -- At the Microscopical Level -- Core Neuropathological Lesion: Cerebral Amyloidosis -- Vascular Alterations -- Neuronal Cytoskeletal Alterations -- Senile Plaques -- Synaptic and Neuronal Loss -- Inflammation -- BEHAVIOR -- Neurological Disorders -- Cognitive Dysfunctions -- Possible Pitfalls in Behavioral Studies of APP Transgenic Mice -- Histological Correlates of Behavioral Impairments -- VALUE OF TRANSGENIC MODELS FOR APPLIED RESEARCH -- Imaging AD-related Brain Lesions in Transgenic Mice -- Modifications Associated to the Amyloid Pathology -- Direct Imaging of Amyloid Lesions -- Usefulness of Tg Models for Preclinical studIes -- Anti-inflammatory Drugs -- Cholesterol-Lowering Drugs -- Metal Chelators -- Immunotherapy -- Other Possible Therapeutic Strategies -- CONCLUSION -- REFERENCES -- Chapter 12 RELEVANCE OF COX-2 INHIBITORS IN ALZHEIMER'S DISEASE -- ABSTRACT -- ALZHEIMER'S DISEASE, INFLAMMATION AND COX-2 INHIBITORS -- CLINICAL IMPLICATIONS OF THE USE OF COX-2 INHIBITORS IN AD PATIENTS -- COX-2 INHIBITORS AND APP PROCESSING: EVIDENCE FROM IN VITRO STUDIES -- EFFECT OF COX-2 INHIBITORS IN VIVO IN TRANSGENIC MOUSE MODELS OF AD -- EFFECT OF COX-2 INHIBITORS ON BEHAVIORAL CHANGES IN MOUSE MODELS OF AD -- FUTURE IMPLICATIONS OF COX-2 INHIBITORS IN THE TREATMENT OF AD -- REFERENCES -- Chapter 13 COPPER STUDIES IN ALZHEIMER'S DISEASE -- ABSTRACT -- INTRODUCTION -- METALLOCHEMISTRY IN AD -- IN VIVO STUDIES IN AD -- CONCLUSION -- ACKNOWLEDGMENTS -- REFERENCES -- Chapter 14 THEORETICAL COMPARISON OF COPPER CHELATORS AS ANTI-ALZHEIMER AND ANTI-PRION AGENTS -- ACKNOWLEDGMENTS -- REFERENCES.

Chapter 15 TOWARD A MORE RATIONAL APPROACH TO THE TREATMENT OF PATIENTS WITH DEMENTIA WITH PSYCHOSIS AND BEHAVIORAL DISTURBANCE -- Chapter 16 AMYLOID CLEARING IMMUNOTHERAPY FOR ALZHEIMER'S DISEASE AND THE RISK OF CEREBRAL AMYLOID ANGIOPATHY -- ABSTRACT -- INTRODUCTION -- IMMUNOTHERAPY -- MECHANISMS OF AB CLEARANCE BY IMMUNOTHERAPY -- CEREBRAL AMYLOID ANGIOPATHY -- CAA ASSOCIATED WITH IMMUNOTHERAPY -- STRATEGIES TO MINIMIZE CAA RISK WITH IMMUNOTHERAPY -- CONCLUSION -- REFERENCES -- Chapter 17 USE OF ANTIDEPRESSANTS IN OLDER PEOPLE WITH MENTAL ILLNESS -- A SYSTEMATIC STUDY OF TOLERABILITY AND USE IN DIFFERENT DIAGNOSTIC GROUPS -- ABSTRACT -- METHOD -- Study Design -- Patient Selection -- Assessments -- Statistical Analysis -- RESULTS -- Patient Characteristics -- Psychoactive Drugs -- Intake of Antidepressants -- Evaluation of Symptoms -- Evaluation of Side-Effects -- DISCUSSION -- ACKNOWLEDGMENTS -- REFERENCES -- Chapter 18 CYSTATIN C ROLE IN ALZHEIMER DISEASE: FROM NEURODEGENERATION TO NEUROREGENERATION -- ABSTRACT -- INTRODUCTION -- The Physiological and Pathological Role of Cystatin C in the Brain -- Cystain C Role in Alzheimer Disease: Molecular Aspects -- Cystain C Role in Alzheimer Disease: Genetic Aspects -- Cystatin C Role in Alzheimer Disease: from Neurodegeneration to Neuroregeneration -- REFERENCES -- Chapter 19 A THEORETICAL EVALUATION ON ACETYLCHOLINESTERASE-INHIBITORY POTENTIAL OF QUERCETIN -- ACKNOWLEDGMENTS -- REFERENCES -- Chapter 20 THERAPY WITH DRUG PRODUCT AZD-103 MAY EASE ALZHEIMER'S DISEASE -- COMPETING INTERESTS -- REFERENCES -- Chapter 21 NSAIDS IN ANIMAL MODELS OF ALZHEIMER'S DISEASE -- ABSTRACT -- INTRODUCTION -- INFLAMMATORY REACTION INDUCED BY A(1-42) INJECTION INTO THE NBM -- IL-1β Production -- COX-2 Immunoreactivity -- Microglia and Astrocyte Activation -- Activation of the p38MAPK Pathway.

iNOS Immunoreactivity and Nitrite Production -- Cholinergic Hypofunction -- EFFECT OF DIFFERENT NSAIDS ON THE INFLAMMATORY REACTION AND NEURONAL DEGENERATION -- Drugs -- CONCLUSION -- REFERENCES -- INDEX -- Blank Page.